Eli Lilly stock surges on Q3 earnings beat driven by strong GLP-1 demand
Eli Lilly reported third-quarter earnings on October 29th that exceeded Wall Street expectations, sending its stock up around 4 to 8 percent. The company posted revenue of 24.4 billion dollars, up 39 percent from a year ago, driven primarily by surging sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro. Those two medications together generated about 16 billion dollars in quarterly sales. In response, Eli Lilly raised its full-year revenue guidance by roughly 5.5 billion dollars to a range of 91 to 92 billion. The company's adjusted earnings per share came in at 7.48 dollars, beating analyst estimates. While prices for the drugs fell 15 percent, sales volume jumped 53 percent globally, more than offsetting the lower prices. The results reflect strong consumer demand for GLP-1 medications, as well as expanded Medicare coverage that began in July through a temporary pilot program.
Key facts
- Eli Lilly Q3 2026 revenue: $24.4 billion, up 39% year-over-year, beating consensus estimates of $22.6 billion
- Mounjaro sales grew 65% to $10.7 billion; Zepbound grew 49% to $5.35 billion in Q3 2026
- Adjusted earnings per share: $7.48, beating analyst expectations of $6.26-$6.50
- Full-year revenue guidance raised to $91-$92 billion from previous guidance of $85-$87 billion
- Tirzepatide (active ingredient in both drugs) volume surged 53% globally despite 15% price decline
- Eli Lilly holds 63% market share of U.S. obesity and diabetes drug market as of Q3 2026
- Lilly captured about 70% of 700,000 Medicare patients who recently initiated GLP-1 treatment
- Annual GLP-1 treatment costs approximately $8,000-$9,000 in U.S. commercial market; approximately $149-$500 monthly through direct-to-consumer channels
How different outlets framed it
Left-leaning coverage: Left-leaning perspectives emphasize that despite Eli Lilly's windfall profits, access to GLP-1 drugs remains deeply unequal, with higher-income patients gaining treatment at nearly double the rate of lower-income populations who bear the greatest burden of obesity and diabetes. Critics argue the company's business model prioritizes shareholder enrichment through patent protections and high pricing over equitable access to life-changing medicines.
Right-leaning coverage: Right-leaning perspectives highlight Eli Lilly's impressive business performance and innovation, noting that the company is efficiently serving growing demand through lower prices and higher volume. Some emphasize that Trump administration pricing negotiations have reduced patient costs, and that market competition—including new pills and future rivals—will naturally drive prices down without government price controls.
Limits of this briefing
This story reflects earnings data from October 29, 2026, and does not capture potential future regulatory changes, competitive pricing pressures from rival manufacturers, or longer-term sustainability questions around insurance coverage at scale. Access disparities remain an ongoing concern not fully resolved by the earnings results alone.
Sources
- CNBC: Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion Centre
- Reuters via Investing.com: Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges Centre
- Eli Lilly Investor Relations (SEC filing): ELI LILLY & Co - Form 8-K - FY2026 Earnings Announcement Centre
- Institute for Clinical and Economic Research / Healthcare equity organizations: Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions Left
- Motley Fool: Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reaction Centre